Islet Cell Carcinoma: Neuroendocrine Tumors of the Pancreas and Periampullary Region

Hematology/Oncology Clinics of North America

Volumn 21, Issue 3, 2007, Pages 457-473

  Nakakura, Eric K ^a   Bergsland, Emily K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ALPHA INTERFERON; ALPHA2B INTERFERON; BEVACIZUMAB; CALCIUM; CHROMOGRANIN A; DIAZOXIDE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; FR 901228; GEFITINIB; INTERFERON; IRINOTECAN; OCTREOTIDE; OXALIPLATIN; PANCREAS POLYPEPTIDE; PASIREOTIDE; PROTON PUMP INHIBITOR; SOMATOSTATIN DERIVATIVE; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; UNINDEXED DRUG; VATALANIB; VON HIPPEL LINDAU PROTEIN; YTTRIUM 90;

CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DRUG WITHDRAWAL; ENZYME INHIBITION; GASTRINOMA; GENE; GENE MUTATION; GLUCAGONOMA; HUMAN; INCIDENCE; INFECTION; INSULINOMA; ISOTOPE LABELING; LIVER TRANSPLANTATION; LYMPHOCYTOPENIA; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; NEUROFIBROMATOSIS; NEUROPATHY; NEUTROPENIA; NF1 GENE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ISLET CELL CARCINOMA; PANCREAS ISLET CELL TUMOR; PANCREAS RESECTION; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TACHYPHYLAXIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUBEROUS SCLEROSIS; ULTRASOUND; UNSPECIFIED SIDE EFFECT; VON HIPPEL LINDAU DISEASE;

CARCINOMA, ISLET CELL; COMMON BILE DUCT NEOPLASMS; HUMANS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; RISK FACTORS;

EID: 34249697053     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.04.005     Document Type: Review

References (57)

1. Solcia E., Kloppel G., and Sobin L.H. Histological typing of endocrine tumors. 2nd edition (2000), Springer-Verlag, Berlin
2. Warner R.R. Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology 128 6 (2005) 1668-1684
3. Perren A., Komminoth P., and Heitz P.U. Molecular genetics of gastroenteropancreatic endocrine tumors. Ann N Y Acad Sci 1014 (2004) 199-208
4. Arnold R. Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options. Best Pract Res Clin Gastroenterol 19 4 (2005) 491-505
5. Kaltsas G.A., Besser G.M., and Grossman A.B. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25 3 (2004) 458-511
6. Rindi G., Leiter A.B., Kopin A.S., et al. The "normal" endocrine cell of the gut: changing concepts and new evidences. Ann N Y Acad Sci 1014 (2004) 1-12
7. Nakakura E.K., Sriuranpong V.R., Kunnimalaiyaan M., et al. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab 90 7 (2005) 4350-4356
8. Klein A., Clemens J., and Cameron J. Periampullary neoplasms in von Recklinghausen's disease. Surgery 106 5 (1989) 815-819
9. Francalanci P., Diomedi-Camassei F., Purificato C., et al. Malignant pancreatic endocrine tumor in a child with tuberous sclerosis. Am J Surg Pathol 27 10 (2003) 1386-1389
10. Verhoef S., van Diemen-Steenvoorde R., Akkersdijk W.L., et al. Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood. Eur J Pediatr 158 4 (1999) 284-287
11. Norton J.A., Fraker D.L., Alexander H.R., et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 341 9 (1999) 635-644
12. Phan G.Q., Yeo C.J., Hruban R.H., et al. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg 2 5 (1998) 472-482
13. Wynick D., Williams S.J., and Bloom S.R. Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors. N Engl J Med 319 10 (1988) 605-607
14. Solorzano C.C., Lee J.E., Pisters P.W., et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 130 6 (2001) 1078-1085
15. Taupenot L., Harper K.L., and O'Connor D.T. The chromogranin-secretogranin family. N Engl J Med 348 12 (2003) 1134-1149
16. Panzuto F., Severi C., Cannizzaro R., et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest 27 1 (2004) 6-11
17. Nehar D., Lombard-Bohas C., Olivieri S., et al. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 60 5 (2004) 644-652
18. Horton K.M. Multidetector CT and three-dimensional imaging of the pancreas: state of the art. J Gastrointest Surg 6 2 (2002) 126-128
19. Noone T.C., Hosey J., Firat Z., et al. Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab 19 2 (2005) 195-211
20. Brugge W.R., Lauwers G.Y., Sahani D., et al. Cystic neoplasms of the pancreas. N Engl J Med 351 12 (2004) 1218-1226
21. McLean A.M., and Fairclough P.D. Endoscopic ultrasound in the localisation of pancreatic islet cell tumours. Best Pract Res Clin Endocrinol Metab 19 2 (2005) 177-193
22. Vezzosi D., Bennet A., Rochaix P., et al. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol 152 5 (2005) 757-767
23. Krausz Y., Keidar Z., Kogan I., et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 59 5 (2003) 565-573
24. Pfannenberg A.C., Eschmann S.M., Horger M., et al. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging 30 6 (2003) 835-843
25. Kaltsas G., Korbonits M., Heintz E., et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 86 2 (2001) 895-902
26. Efron D.T., Lillemoe K.D., Cameron J.L., et al. Central pancreatectomy with pancreaticogastrostomy for benign pancreatic pathology. J Gastrointest Surg 8 5 (2004) 532-538
27. Norton J.A., and Jensen R.T. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 240 5 (2004) 757-773
28. Madeira I., Terris B., Voss M., et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 43 3 (1998) 422-427
29. Hirshberg B., Cochran C., Skarulis M.C., et al. Malignant insulinoma: spectrum of unusual clinical features. Cancer 104 2 (2005) 264-272
30. Chamberlain R.S., Canes D., Brown K.T., et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 190 4 (2000) 432-445
31. Touzios J.G., Kiely J.M., Pitt S.C., et al. Neuroendocrine hepatic metastases: does aggressive management improve survival?. Ann Surg 241 5 (2005) 776-783 [discussion: 783-785]
32. Sarmiento J.M., Heywood G., Rubin J., et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197 1 (2003) 29-37
33. Chen H., Hardacre J.M., Uzar A., et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?. J Am Coll Surg 187 1 (1998) 88-92 [discussion: 92-93]
34. Le Treut Y.P., Delpero J.R., Dousset B., et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg 225 4 (1997) 355-364
35. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation 66 10 (1998) 1307-1312
36. Gupta S., Johnson M.M., Murthy R., et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors. Cancer 104 8 (2005) 1590-1602
37. Eriksson B.K., Larsson E.G., Skogseid B.M., et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83 11 (1998) 2293-2301
38. Moertel C.G., Lefkopoulo M., Lipsitz S., et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 8 (1992) 519-523
39. Cheng P.N., and Saltz L.B. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86 6 (1999) 944-948
40. Kouvaraki M.A., Ajani J.A., Hoff P., et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22 23 (2004) 4762-4771
41. Kulke M.H., Stuart K., Enzinger P.C., et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24 3 (2006) 401-406
42. Oberg K., and Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 19 5 (2005) 753-781
43. di Bartolomeo M., Bajetta E., Buzzoni R., et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77 2 (1996) 402-408
44. Faiss S., Pape U.F., Bohmig M., et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21 14 (2003) 2689-2696
45. Shah T., and Caplin M. Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 19 4 (2005) 617-636
46. Pavel M.E., Baum U., Hahn E.G., et al. Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res 26 1 (2006) 8-13
47. Schmid H.A., and Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80 Suppl 1 (2004) 47-50
48. Kwekkeboom D.J., Mueller-Brand J., Paganelli G., et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46 Suppl 1 (2005) 62S-66S
49. Valkema R., Pauwels S., Kvols L.K., et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36 2 (2006) 147-156
50. Terris B., Scoazec J., Rubbia L., et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 32 2 (1998) 133-138
51. Yao J.C., Ng C., Hoff P., et al. Improved pregression free survival (PVS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab. Proc Am Soc Clin Oncol (2005) [abstract 4007]:72
52. Inoue M., Hager J.H., Ferrara N., et al. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1 2 (2002) 193-202
53. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3 6 (2003) 401-410
54. Konno H., Arai T., Tanaka T., et al. Antitumor effect of a neutralizing antibody to vascular endothelial growth factor on liver metastasis of endocrine neoplasm. Jpn J Cancer Res 89 9 (1998) 933-939
55. Cohen T., Herzog Y., Brodzky A., et al. Neuropilin-2 is a novel marker expressed in pancreatic islet cells and endocrine pancreatic tumours. J Pathol 198 1 (2002) 77-82
56. Fjallskog M.L., Lejonklou M.H., Oberg K.E., et al. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 9 4 (2003) 1469-1473
57. Kulke M., Lenz H.J., Meropol N.J., et al. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). Proc Am Soc Clin Oncol (2005) [abstract #4008:310s]:72